Insulin resistance in heart failure: Widening the divide between reduced and preserved ejection fraction?

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 991-993

  Greene, Stephen J ^a   Fonarow, Gregg C ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN;

COHORT ANALYSIS; COMORBIDITY; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; ECHOCARDIOGRAPHY; EDITORIAL; EVIDENCE BASED MEDICINE; EXERCISE TEST; GLYCEMIC CONTROL; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN SENSITIVITY; LEAN BODY WEIGHT; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRESERVED HEART LEFT VENTRICLE EJECTION FRACTION; PRIORITY JOURNAL; PROGNOSIS; REDUCED HEART LEFT VENTRICLE EJECTION FRACTION; SYMPTOM; FEMALE; HEART STROKE VOLUME; MALE; PHYSIOLOGY;

FEMALE; HEART FAILURE; HUMANS; INSULIN RESISTANCE; MALE; STROKE VOLUME;

EID: 84946480570     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.337     Document Type: Editorial

References (17)

1. Braunwald E., The war against heart failure: the Lancet lecture. Lancet 2015; 385: 812-824.
2. Steinberg BA, Zhao X, Heidenreich PA, Peterson ED, Bhatt DL, Cannon CP, Hernandez AF, Fonarow GC,. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012; 126: 65-75.
3. Paulus WJ, Tschope C,. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol 2013; 62: 263-271.
4. Das SR, Drazner MH, Yancy CW, Stevenson LW, Gersh BJ, Dries DL,. Effects of diabetes mellitus and ischemic heart disease on the progression from asymptomatic left ventricular dysfunction to symptomatic heart failure: a retrospective analysis from the Studies of Left Ventricular Dysfunction (SOLVD) Prevention trial. Am Heart J 2004; 148: 883-888.
5. MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB, Solomon SD, Granger CB, Swedberg K, Yusuf S, Pfeffer MA, McMurray JJ,. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 2008; 29: 1377-1385.
6. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM,. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol 2014; 64: 2281-2293.
7. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC,. Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 2015; 3: 136-145.
8. Khan SS, Butler J, Gheorghiade M,. Management of comorbid diabetes mellitus and worsening heart failure. JAMA 2014; 311: 2379-2380.
9. Scherbakov N, Bauer M, Sandek A, Szabo T, Topper A, Jankowska EA, Springer J, von Haehling S, Anker SD, Lainscak M, Engeli S, Dungen H, Doehner W,. Insulin resistance in heart failure: differences between patients with reduced and preserved left ventricular ejection fraction. Eur J Heart Fail 2015; 17:XXX-XXX.
10. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO, Leyva F, Proudler AJ, Coats AJ, Anker SD,. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005; 46: 1019-1026.
11. Wisniacki N, Taylor W, Lye M, Wilding JP,. Insulin resistance and inflammatory activation in older patients with systolic and diastolic heart failure. Heart 2005; 91: 32-37.
12. Doehner W., Critical appraisal of the obesity paradox in cardiovascular disease: how to manage patients with overweight in heart failure? Heart Fail Rev 2014; 19: 637-644.
13. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE,. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2011; 4: 324-331.
14. Greene SJ, Vaduganathan M, Lupi L, Ambrosy AP, Mentz RJ, Konstam MA, Nodari S, Subacius HP, Fonarow GC, Bonow RO, Gheorghiade M,. Prognostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol 2013; 111: 574-581.
15. Aguilar D, Bozkurt B, Ramasubbu K, Deswal A,. Relationship of hemoglobin A1C and mortality in heart failure patients with diabetes. J Am Coll Cardiol 2009; 54: 422-428.
16. Action to Control Cardiovascular Risk in Diabetes Study GROUP, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT,. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559.
17. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ,. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.